Skip to main content

Advertisement

SpringerLink
Log in

Pharmacologic Strategies for the Prevention of Stroke in Patients With Atrial Fibrillation

  • Arrhythmia
  • Published:
Current Treatment Options in Cardiovascular Medicine Aims and scope Submit manuscript

Opinion statement

Stroke is a dreaded complication of atrial fibrillation. In the past, preventive therapy included aspirin and oral anticoagulation. Selected patients who are not suitable for oral anticoagulation may benefit from the addition of clopidogrel with aspirin. This combination, when compared with aspirin, offers a reduced risk of stroke at a cost of more major bleeding. We use this therapy in patients with atrial fibrillation who have unstable coronary syndromes or in patients who receive coronary artery stents who are not good candidates for “triple therapy” with aspirin, clopidogrel, and warfarin. The duration of therapy is tempered by many variables. In the case of coronary stents, we ask the interventionalist to consider a bare metal stent to shorten the duration of need for clopidogrel plus aspirin. After several months of combination therapy, we stop this therapy and begin warfarin therapy. Dabigatran is commercially available in the United States. In patients who have difficult to control International Normalized Ratio (INR) values or who do not wish to have regular coagulation monitoring, dabigatran offers a huge advantage. The benefit seems less if the INR is consistently within range. We are impressed with the superior reduction in stroke and systemic embolism with 150 mg of dabigatran twice daily compared to warfarin and also its low risk of intracranial hemorrhage. The results of clinical trials involving factor Xa agents are now being presented. How these agents fit into the marketplace remains to be seen but they will offer clinicians additional therapy for stroke prevention in atrial fibrillation.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Figure 1

Similar content being viewed by others

References and Recommended Reading

Papers of particular interest, published recently, have been highlighted as: •• Of major importance

  1. Hart RG, Lesly AP, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Int Med. 2007;146(12):857–67.

    PubMed  Google Scholar 

  2. Laupacis A, Albers G, Dunn M, Feinberg W. Antithrombotic therapy in atrial fibrillation. Chest. 1992;102(suppl):426S–33S.

    Article  PubMed  CAS  Google Scholar 

  3. Kumagai K, Fukunami M, Ohmori M, et al. Increased intracardiovascular clotting in patients with chronic atrial fibrillation. J Am Coll Cardiol. 1990;16:377–80.

    Article  PubMed  CAS  Google Scholar 

  4. Gustafsson C, Blomback M, Britton M, Hamsten A, Svensson J. Coagulation factors and the increased risk of stroke in nonvalvular atrial fibrillation. Stroke. 1990;21:47–51.

    Article  PubMed  CAS  Google Scholar 

  5. Lip GY, Lowe GD, Rumley A, Dunn FG. Increased markers of thrombogenesis in chronic atrial fibrillation: effects of warfarin treatment. Br Heart J. 1995;73:527–33.

    Article  PubMed  CAS  Google Scholar 

  6. Asakura H, Hifumi S, Jokaji H, et al. Prothrombin fragment F1+2 and thrombin-antithrombin III complex are useful markers of the hypercoagulable state in atrial fibrillation. Blood Coagul Fibrinolysis. 1992;3:469–73.

    PubMed  CAS  Google Scholar 

  7. Kamath S, Blann AD, Chin BS, et al. A study of platelet activation in atrial fibrillation and the effects of antithrombotic therapy. Eur Heart J. 2002;23:1788–95.

    Article  PubMed  CAS  Google Scholar 

  8. Heeringa J, Conway DS, van der Kuip DA, et al. A longitudinal population-based study of prothrombotic factors in elderly subjects with atrial fibrillation: the Rotterdam Study 1990–1999. J Thromb Haemost. 2006;4:1944–9.

    Article  PubMed  CAS  Google Scholar 

  9. Feng D, D’Agostino RB, Silbershatz H, et al. Hemostatic state and atrial fibrillation (The Framingham Offspring Study). Amer J Cardiol. 2001;87:168–71.

    Article  PubMed  CAS  Google Scholar 

  10. Lip GYH, Lip PL, Zarifis J, et al. Fibrin D-dimer and beta-thromboglobulin as markers of thrombogenesis and platelet activation in atrial fibrillation. Effects of introducing ultra-low-dose of warfarin and aspirin. Circulation. 1996;94:425–31.

    PubMed  CAS  Google Scholar 

  11. Kamath S, Blann AD, Chin BS, Lip GY. A prospective randomized trial of aspirin-clopidogrel combination therapy and dose-adjusted warfarin on indices of thrombogenesis and platelet activation in atrial fibrillation. J Am Coll Cardiol. 2002;40:484–90.

    Article  PubMed  CAS  Google Scholar 

  12. Sadangara T, Sadanaga M, Ogawa S. Evidence that d-Dimer levels predict subsequent thromboembolic and cardiovascular events in patients with atrial fibrillation during oral anticoagulant therapy. JACC. 2010;55:2225–31.

    Google Scholar 

  13. Feinberg WM, Pearce LA, Hart RG, et al. Markers of thrombin and platelet activity in patients with atrial fibrillation: correlation with stroke among 1531 participants in the stroke prevention in atrial fibrillation III study. Stroke. 1999;30:2547–53.

    Article  PubMed  CAS  Google Scholar 

  14. Connolly S, Pogue J, Hart R, et al. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial. Lancet. 2006;367:1903–12.

    Article  PubMed  CAS  Google Scholar 

  15. Connolly SJ, Pogue J, Hart RG, et al.: Effect of clopidogrel added to aspirin in patients with atrial fibrillation. N Engl J Med 2009;360:2066–78.

    Article  PubMed  Google Scholar 

  16. 2011 ACCF/AHA/HRS Focused Update on the Management of Patients with Atrial Fibrillation (Updating the 2006 Guideline)ACC/AHA guidelines. JACC 2011;57:223–42.

  17. Executive Steering Committee on behalf of the SPORTIF III Investigators. Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): randomised controlled trial. Lancet. 2003;362:1691–8.

    Article  Google Scholar 

  18. SPORTIF Executive Steering Committee for the SPORTIF V Investigators. Ximelagatran vs warfarin for stroke prevention in patients with nonvalvular atrial fibrillation: a randomized trial. JAMA. 2005;293(6):690–8.

    Article  Google Scholar 

  19. Connolly SJ, Ezekowitz MD, Yusuf S, et al.: Dabigatran versus warfarin in patients with atrial fibrillation. NEJM 2009;361(12):1139–202. Correction NEJM 2010;363:11875–6.

    Article  PubMed  CAS  Google Scholar 

  20. Fiessinger JN, Huisman MV, Davidson BL, et al. Ximelagatran vs. low molecular weight heparin and warfarin for the treatment of deep vein thrombosis: a randomized trial. JAMA. 2005;293:681–9.

    Article  PubMed  CAS  Google Scholar 

  21. Shulman S, Wahlander K, Lundstrom T, THRIVE III Investigators, et al. Secondary prevention of venous thromboembolism with the oral direct thrombin inhibitor ximelagatran. N Engl J Med. 2003;248:1713–21.

    Article  Google Scholar 

  22. Wallentin L, Wilcox R, Weaver W, et al. Oral ximelagatran for secondary prophylaxis after myocardial infarction: the ESTEEM randomized controlled trial. Lancet. 2003;362(9386):789–97.

    Article  PubMed  CAS  Google Scholar 

  23. The Direct Thrombin Inhibitors Investigators. Direct thrombin inhibitors in acute coronary syndromes: principal results of a meta-analysis based on individual patients’ data. Lancet. 2002;359(9303):294–302.

    Article  Google Scholar 

  24. Eriksson BI, Dahl OE, Rosencher N, et al. Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomized, double-blind, non-inferiority trial. Lancet. 2007;370(9591):949–55.

    Article  PubMed  CAS  Google Scholar 

  25. Eriksson BI, Dahl OE, Rosencher N, et al. Oral dabigatrann etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolisms after total knee replacement: the RE-MODEL randomized trial. J Thromb Haemost. 2007;5(11):2178–85.

    Article  PubMed  CAS  Google Scholar 

  26. The RE-MOBILIZE Writing committee. The oral thrombin inhibitor dabigatran etexilate vs. the North American enoxaparin regimen for the prevention of venous thromboembolism after knee arthroplasty surgery. J Arthroplasty. 2009;24(1):1–9.

    Article  Google Scholar 

  27. Stangier J, Rathgen K, Stahle H, et al. The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in health male subjects. Br J Clin Pharmacology. 2007;64(3):292–303.

    Article  CAS  Google Scholar 

  28. Freeman J, Zhu R, Owens DK et al. Cost Effectiveness of dabigatran compared with warfarin for stroke prevention in atrial fibrillation. Annals Int Med 2010.

  29. Wallentin L, Yusuf S, Ezekowitz MD, et al. Efficacy and safety of dabigatran compared with warfarin at different levels of international normalized ration control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial. Lancet. 2010;376:975–83.

    Article  PubMed  CAS  Google Scholar 

  30. The AMADEUS Investigators. Comparison of idraparinux with vitamin K antagonists for prevention of thromboembolism in patients with atrial fibrillation: a randomized, open-label, non-inferiority trial. Lancet. 2008;371:315–21.

    Article  Google Scholar 

  31. Connolly SJ, Eikelboom J, Joyner C, et al. Apixaban in patients with atrial fibrillation unsuitable for vitamin K antagonists. New England J Feb 10, 2011;364:806–17.

    Google Scholar 

  32. The Executive Steering Committee, on behalf of the ROCKET AF Study Investigators. Rivaroxaban-once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation: Rationale and design of the ROCKET AF study. Amer Heart J. 2010;159:340–7.

    Article  Google Scholar 

  33. ROCKET-AF. Presented at the American Heart Association meeting 2010.

Download references

Disclosure

G. Flaker has received consulting fees from Sanofi Aventis and Bristol-Myers Squibb. He has received support for travel to meetings from Boehringer Ingelheim and Bristol-Myers Squibb, and his institution has received grant money from Boehringer Ingelheim and Bristol-Myers Squibb. R. Weachter reports no potential conflict of interest relevant to this article.

Author information

Authors and Affiliations

  1. Division of Cardiovascular Medicine, University of Missouri-Columbia, Five Hospital Drive, CE306, Columbia, MO, 65212, USA

    Greg Flaker MD & Richard Weachter MD

Authors
  1. Greg Flaker MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Richard Weachter MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Greg Flaker MD.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Flaker, G., Weachter, R. Pharmacologic Strategies for the Prevention of Stroke in Patients With Atrial Fibrillation. Curr Treat Options Cardio Med 13, 361–369 (2011). https://doi.org/10.1007/s11936-011-0139-4

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11936-011-0139-4

Keywords

Search

Navigation